Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma

Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma

Background: CDK9 inhibitors are antitumorigenic against solid tumors, including esophageal adenocarcinoma (EAC). However, efficacy of a CDK9 inhibitor combined with 5-fluorouracil (5-FU) and target proteins that are targeted by these agents in EAC are unknown. Methods: The anti-EAC efficacy of a new...

Full description

Bibliographic Details
Main Authors: Zhimin Tong, Alicia Mejia, Omkara Veeranki, Anuj Verma, Arlene M. Correa, Rashmi Dokey, Viren Patel, Luisa Maren Solis, Barbara Mino, Riham Kathkuda, Jaime Rodriguez-Canales, Steven H. Lin, Sunil Krishnan, Scott Kopetz, Mariela Blum, Jaffer A. Ajani, Wayne L. Hofstetter, Dipen M. Maru
Format: Article
Language:English
Published: SAGE Publishing 2019-07-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835919864850

Internet

https://doi.org/10.1177/1758835919864850

Similar Items